Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

Recent Analyst Ratings for
$CG

$CG
SEC Filings

$CG
Leadership Updates

$CG
Press Releases

$CG
Analyst Ratings

$CG
Financials

$CG
Insider Trading

$CG
Large Ownership Changes

Chat with this insight

Amendment: SEC Form SCHEDULE 13G/A filed by The Carlyle Group Inc.

SEC Form 13F-HR filed by The Carlyle Group Inc.

SEC Form 10-Q filed by The Carlyle Group Inc.

Live Leadership Updates

SoftBank Group to Acquire Ampere Computing

Acentra Health Welcomes Distinguished Public Sector Health Leaders Calder Lynch and Jami Snyder to its Healthcare Advisory Board; Appoints Julie Boughn as New Chair

Acentra Health Appoints Ezmeralda Sager as Chief Transformation Officer

Fastest customizable press release news feed in the world

Resonetics® Invests in Nitinol Gun Drilling Capabilities Through Purchase of Assets from Medical Component Specialists

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Live finance-specific insights

Carlyle Group upgraded by TD Cowen with a new price target

Carlyle Group downgraded by Oppenheimer

Carlyle Group upgraded by Wolfe Research with a new price target

Carlyle Secured Lending, Inc. Announces Financial Results For First Quarter Ended March 31, 2025, Declares Second Quarter 2025 Dividend of $0.40 Per Common Share

Carlyle Credit Income Fund Schedules Second Quarter Financial Results and Investor Conference Call

Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the First Quarter Ended March 31, 2025

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Carlyle Group Inc. sold $668,171,267 worth of shares (24,475,138 units at $27.30) (SEC Form 4)

Director Filler Linda was granted 5,235 shares, increasing direct ownership by 32% to 21,713 units (SEC Form 4)

Director Beschloss Afsaneh Mashayekhi was granted 5,235 shares, increasing direct ownership by 105% to 10,239 units (SEC Form 4)

This live feed shows all institutional transactions in real time.

10/15/24 4:31:27 PM ET

$CG

Investment Managers

Finance

Get the next $CG alert in real time by email

SC 13D/A 1 d726271dsc13da.htm SC 13D/A SC 13D/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 11)*

Soleno Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

834203200

(CUSIP Number)

Jeffrey Ferguson

The Carlyle Group

1001 Pennsylvania Avenue, NW

Suite 220 South

Washington, D.C. 20004

(202) 729-5626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 10, 2024

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 834203200		13D		Page 1 of 15 pages


1		Names of Reporting Persons The Carlyle Group Inc.
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 2 of 15 pages


1		Names of Reporting Persons Carlyle Holdings I GP Inc.
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 3 of 15 pages


1		Names of Reporting Persons Carlyle Holdings I GP Sub L.L.C.
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 4 of 15 pages


1		Names of Reporting Persons Carlyle Holdings I L.P.
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 5 of 15 pages


1		Names of Reporting Persons CG Subsidiary Holdings L.L.C.
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 6 of 15 pages


1		Names of Reporting Persons TC Group, L.L.C.
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 7 of 15 pages


1		Names of Reporting Persons Carlyle Investment Management L.L.C.
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 8 of 15 pages


1		Names of Reporting Persons Carlyle Genesis UK LLC
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization Delaware


CUSIP No. 834203200		13D		Page 9 of 15 pages


1		Names of Reporting Persons Abingworth LLP
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization England and Wales


CUSIP No. 834203200		13D		Page 10 of 15 pages


1		Names of Reporting Persons Abingworth Bioventures VII LP
2		Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
3		SEC Use Only
4		Source of Funds (See Instructions) OO
5		Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6		Citizenship or Place of Organization England and Wales


CUSIP No. 834203200		13D		Page 11 of 15 pages

Explanatory Note

This Amendment No. 11 to Schedule 13D (“Amendment No. 11”) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission on December 27, 2018 (as amended to date, the “Schedule 13D”), relating to the shares of common stock, par value $0.001 per share (the “Common Stock”), of Soleno Therapeutics, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.


CUSIP No. 834203200		13D		Page 12 of 15 pages

Item 5.

Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a) – (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 40,108,265 shares of Common Stock, which includes (i) 38,871,594 shares of Common Stock outstanding as of August 2, 2024, as disclosed in the Issuer’s quarterly report on Form 10-Q filed on August 7, 2024, (ii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof and (iii) 1,213,758 shares of Common Stock underlying the Prefunded Warrants, all of which are currently exercisable.


Reporting Person	Amount beneficially owned		Percent of class			Sole power to vote or to direct the vote		Shared power to vote or to direct the vote		Sole power to dispose or to direct the disposition		Shared power to dispose or to direct the disposition
The Carlyle Group Inc.		2,468,099		6.2	%		0		2,468,099		0		2,468,099
Carlyle Holdings I GP Inc.		2,468,099		6.2	%		0		2,468,099		0		2,468,099
Carlyle Holdings I GP Sub L.L.C.		2,468,099		6.2	%		0		2,468,099		0		2,468,099
Carlyle Holdings I L.P.		2,468,099		6.2	%		0		2,468,099		0		2,468,099
CG Subsidiary Holdings L.L.C.		2,468,099		6.2	%		0		2,468,099		0		2,468,099
TC Group, L.L.C.		2,468,099		6.2	%		0		2,468,099		0		2,468,099
Carlyle Investment Management L.L.C.		2,468,099		6.2	%		0		2,468,099		0		2,468,099
Carlyle Genesis UK LLC		2,468,099		6.2	%		0		2,468,099		0		2,468,099
Abingworth LLP		2,468,099		6.2	%		0		2,468,099		0		2,468,099
Abingworth Bioventures VII LP		2,468,099		6.2	%		0		2,468,099		0		2,468,099

The amount of Common Stock reported as beneficially owned above includes (i) 1,224,928 shares of Common Stock held of record by Abingworth Bioventures VII LP, (ii) 6,500 shares of Common Stock held of record by Andrew Sinclair for the benefit of Abingworth Bioventures VII LP (iii) 22,913 shares of Common Stock underlying stock options exercisable within 60 days as of the date hereof and (iv) 1,213,758 shares of Common Stock underlying a portion of the Prefunded Warrants, which are currently exercisable.

The amount of securities disclosed excludes 514,666 shares of Common Stock underlying the March 2022 Warrants, which contain a provision prohibiting exercise to the extent that the holder, together with its affiliates, would beneficially own in excess of 4.99% of the total number of shares of Common Stock then issued and outstanding.


CUSIP No. 834203200		13D		Page 13 of 15 pages

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by Abingworth Bioventures VII LP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.

(c) From October 9, 2024 through October 11, 2024, Abingworth Bioventures VII LP disposed of 782,979 shares of Common Stock in a series of open market transactions pursuant to the 10b5-1 Plan. Details by date, listing the number of shares of Common Stock disposed of and the weighted average price per share, are provided below. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for each transaction.


Date	Shares Disposed Of		Price Range		Weighted Average Price Per Share
October 9, 2024		255,963	$	50.355 to $52.00	$	51.0507
October 10, 2024		182,489	$	49.585 to $51.76	$	50.6347
October 11, 2024		344,527	$	50.85 to $54.815	$	54.0930

(d) None.

(e) Not applicable.


CUSIP No. 834203200		13D		Page 14 of 15 pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 15, 2024


The Carlyle Group Inc.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Chief Financial Officer

Carlyle Holdings I GP Inc.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Managing Director and Chief Financial Officer

Carlyle Holdings I GP Sub L.L.C.
By: Carlyle Holdings I GP Inc., its sole member

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Managing Director and Chief Financial Officer

Carlyle Holdings I L.P.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Managing Director

CG Subsidiary Holdings L.L.C.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Managing Director

TC Group, L.L.C.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Managing Director


CUSIP No. 834203200		13D		Page 15 of 15 pages


Carlyle Investment Management L.L.C.

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Chief Financial Officer

Carlyle Genesis UK LLC
By: Carlyle Investment Management L.L.C., its sole member

By:		/s/ Anne Frederick, attorney-in-fact
Name:		John C. Redett
Title:		Chief Financial Officer

Abingworth LLP

By:		/s/ John Heard
Name:		John Heard
Title:		Authorized Signatory

Abingworth Bioventures VII LP

By:		/s/ John Heard
Name:		John Heard
Title:		Authorized Signatory

Get the next $CG alert in real time by email

Date	Price Target	Rating	Analyst
5/14/2025	$56.00	Hold → Buy	TD Cowen
3/19/2025		Outperform → Perform	Oppenheimer
1/3/2025	$60.00	Peer Perform → Outperform	Wolfe Research
9/12/2024	$42.00	Equal Weight	Wells Fargo
8/27/2024	$55.00	Buy	Redburn Atlantic
8/6/2024	$46.00 → $44.00	Overweight → Neutral	JP Morgan
1/19/2024	$40.00 → $41.00	Buy → Neutral	Citigroup
1/4/2024	$42.00	Market Perform	TD Cowen

NUMBER OF

SHARES BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

Sole Voting Power

0

Shared Voting Power

2,468,099

Sole Dispositive Power

0

Shared Dispositive Power

2,468,099